Staufen1在人类神经退行性疾病中的作用
该研究利用多种神经退行性疾病患者来源的细胞模型、动物模型及人ALS死后组织,发现STAU1蛋白过丰与mTOR过度激活在ALS、痴呆、帕金森综合征、亨廷顿病和SCA2中普遍存在。STAU1过表达足以激活mTOR并形成应激颗粒,RNAi靶向STAU1可恢复正常mTOR水平,提示靶向STAU1可能成为新疗法。
要点
- STAU1过丰与mTOR过度激活在多种神经退行性疾病中普遍存在。
- STAU1过表达足以激活mTOR并诱导应激颗粒形成。
- RNAi靶向STAU1可恢复正常mTOR水平,提示治疗潜力。
核心结论
- STAU1过丰是神经退行性疾病中的常见现象,与mTOR过度激活相关。
研究设计与样本
- 研究使用多种神经退行性疾病患者来源的细胞模型、动物模型及人ALS死后组织,通过生化与免疫组化分析评估STAU1功能。
主要发现
- 在ALS(TDP-43突变)、PSEN1突变痴呆、MAPT突变帕金森综合征、亨廷顿病及SCA2患者成纤维细胞中均观察到STAU1过丰及总mTOR和磷酸化mTOR增加。
- 人ALS脊髓组织及动物模型中亦见STAU1水平升高和mTOR活性增强。
- STAU1与mTOR蛋白水平变化发生于转录后水平。
- 在野生型细胞中外源性表达STAU1足以激活mTOR及其下游靶点并形成应激颗粒。
- RNAi靶向STAU1可使mTOR水平正常化。
临床怎么用
- 靶向STAU1(如ASO或miRNA病毒载体)可能成为以STAU1过丰为特征的神经退行性疾病的新型治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mutations in the ATXN2 gene (CAG expansions ≥32 repeats) can be a rare cause of Parkinson's disease and amyotrophic lateral sclerosis (ALS). We recently reported that the stress granule (SG) protein Staufen1 (STAU1) was overabundant in neurodegenerative disorder spinocerebellar ataxia type 2 (SCA2) patient cells, animal models, and ALS-TDP-43 fibroblasts, and provided a link between SG formation and autophagy. We aimed to test if STAU1 overabundance has a role in the pathogenesis of other neurodegenerative diseases. METHODS: With multiple neurodegenerative patient-derived cell models, animal models, and human postmortem ALS tissue, we evaluate STAU1 function using biochemical and immunohistological analyses. RESULTS: We demonstrate STAU1 overabundance and increased total and phosphorylated mammalian target of rapamycin (mTOR) in fibroblast cells from patients with ALS with mutations in TDP-43, patients with dementia with PSEN1 mutations, a patient with parkinsonism with MAPT mutation, Huntington's disease (HD) mutations, and SCA2 mutations. Increased STAU1 levels and mTOR activity were seen in human ALS spinal cord tissues as well as in animal models. Changes in STAU1 and mTOR protein levels were post-transcriptional. Exogenous expression of STAU1 in wildtype cells was sufficient to activate mTOR and downstream targets and form SGs. Targeting STAU1 by RNAi normalized mTOR, suggesting a potential role for therapy in diseases associated with STAU1 overabundance. INTERPRETATION: STAU1 overabundance in neurodegeneration is a common phenomenon associated with hyperactive mTOR. Targeting STAU1 with ASOs or miRNA viral vectors may represent a novel, efficacious therapy for neurodegenerative diseases characterized by overabundant STAU1. ANN NEUROL 2021;89:1114-1128.
引用
- Paul S, Dansithong W, Figueroa KP, et al. Staufen1 in Human Neurodegeneration. Ann Neurol. 2021. PMID: 33745139. doi:10.1002/ana.26069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。